The transformative potential of HSC gene therapy as a genetic medicine.
Pervinder SagooH Bobby GasparPublished in: Gene therapy (2021)
Hematopoietic stem cells (HSCs) are precursor cells that give rise to blood, immune and tissue-resident progeny in humans. Their position at the starting point of hematopoiesis offers a unique therapeutic opportunity to treat certain hematologic diseases by implementing corrective changes that are subsequently directed through to multiple cell lineages. Attempts to exploit HSCs clinically have evolved over recent decades, from initial approaches that focused on transplantation of healthy donor allogeneic HSCs to treat rare inherited monogenic hematologic disorders, to more contemporary genetic modification of autologous HSCs offering the promise of benefits to a wider range of diseases. We are on the cusp of an exciting new era as the transformative potential of HSC gene therapy to offer durable delivery of gene-corrected cells to a range of tissues and organs, including the central nervous system, is beginning to be realized. This article reviews the rationale for targeting HSCs, the approaches that have been used to date for delivering therapeutic genes to these cells, and the latest technological breakthroughs in manufacturing and vector design. The challenges faced by the biotechnology cell and gene therapy sector in the commercialization of HSC gene therapy are also discussed.
Keyphrases
- gene therapy
- induced apoptosis
- stem cells
- cell cycle arrest
- cell therapy
- genome wide
- bone marrow
- single cell
- endoplasmic reticulum stress
- copy number
- gene expression
- cell death
- oxidative stress
- stem cell transplantation
- signaling pathway
- cell proliferation
- drug delivery
- systematic review
- risk assessment
- cancer therapy
- cerebrospinal fluid
- quality improvement
- deep learning